A Phase 1/2 interventional study of RX-3117 in Metastatic Pancreatic Cancer, sponsored by Processa Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.
Sponsored by Processa Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 658th largest by enrollment of the 1,573 interventional ones that give a count, is one of 101 that started in 2017, is one of 222 in phase 1/2, and was the 1,072nd registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 777 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 101 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is close to the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,573 interventional studies, 137 across the 230 observational. Of the 1,223 that completed or were terminated, 479 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
576 of 1,850 have an industry lead sponsor. The 10 most frequent:
Processa Pharmaceuticals is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Processa Pharmaceuticals has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
161 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 161 to your calendar (.ics) → With an account.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. The recommended phase 2 dose (RP2D) and schedule of RX-3117, in combination with Abraxane®, will be determined based on the safety profile, dose modification, and pharmacokinetics (PK). Phase 1 will be conducted using a combination of the single agent maximum tolerated dose (MTD) for RX-3117 and the Abraxane dose as per the package insert for patients with pancreatic cancer in combination with gemcitabine.
After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy. Approximately 10 subjects will participate in the Stage 1 at the dose identified in Phase 1 (RP2D). Subjects will be treated for up to 8 cycles of combined therapy. An interim analysis will be conducted after 10 evaluable subjects have been treated at the RP2D, have completed a minimum of 4 cycles of therapy, or have discontinued therapy due to progressive disease before completing 4 cycles. If an adequate number of Responders are observed out of the initial 10 evaluable subjects, then 40 additional subjects will be enrolled to participate in Stage 2. Subjects will be treated for up to 8 cycles of combined therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease Related
Subject has an (ECOG) performance status 0 or 1.
Demographic
Subject must have adequate venous access for intravenous (IV) infusion
Laboratory
For women of : Negative serum pregnancy test during screening and negative serum or urine pregnancy test at start of study therapy (Cycle1 Day 1).
Reproductive
For fertile male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the start of study therapy throughout the study treatment period and for 30 days following the last dose of study drug and to refrain from sperm donation from the start of study treatment throughout the study treatment period and for 30 days following the last dose of study drug.
Ethical
Exclusion Criteria:
Disease Related
Subject has undergone major surgery within 4 weeks of the start of study treatment. Laparoscopy and central venous catheter placement are not considered major surgery
Medications
Subject has a history of systemic use within 7 days before Day 1 of Cycle 1
General
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle. Abraxane: 75 - 125 mg/m\^2, infused once per week for 3 weeks. 1 washout week/ cycle.
Drug: RX-3117
RX-3117 will be administered orally in combination with Abraxane.
Also known as: Abraxane
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)
Number of participants who experienced a treatment-related adverse event
Time frame: 9 months
Number of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2)
Participants with adverse events coded using the MedDRA Dictionary (Version 20.0) to Investigations. Due to the underlying disease, not all abnormal labs are reported.
Time frame: 9 months
Number of Participants With Vital Sign Abnormalities (Phase 1 and 2)
Number of participants with clinically significant vital sign abnormalities (Phase 1 and 2) including heart rate, respiration rate, and blood pressure
Time frame: 9 months
Number of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2)
Number of participants with clinically significant ECG abnormalities (Phase 1 and 2)
Time frame: 1 month
Number of Dose-limiting Toxicities (DLTs) (Phase 1)
Time frame: 4 weeks
Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2)
Participants must have progression Free Survival (PFS) \> 4 months or objective clinical response (complete or partial response).
Time frame: 9 months
Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 1
Time frame: Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 1
Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 1
Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Overall Response Rate [ORR] (Phase 1 and Phase 2)
Overall Response Rate will be based on the RECIST v1.1 and is defined as the percentage of subjects meeting criteria of Complete Response (CR) or Partial Response (PR). CR or PR must be confirmed at least 4 weeks after the date of the original CR or PR.
Time frame: Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Time to Response [TTR] (Phase 1)
Time frame: Up to 32 weeks
Duration of Response [DOR] (Phase 1 and Phase 2)
Duration of response is defined as the time from documentation of response to disease progression.
Time frame: Up to 32 weeks
Progression-free Survival [PFS] (Phase 1)
Progression Free Survival defined as the percentage of subjects who are alive in the study and not in progression.
Time frame: Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Time to Progression (Phase 2)
Time to Progression defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression.
Time frame: Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 15
Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 1
Time frame: Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 15
Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 15
Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 1
Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 15
Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15
Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 1
Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15
Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Exploratory Measurement of Protein Biomarkers Related to RX-3117 or Pancreatic Cancer (Phase 1 and 2)
Time frame: Baseline, and at 8, 6, 24, and 32 weeks
Tumor Burden Response (Phase 2)
Changes in tumor burden response via tumor marker measurement
Time frame: Baseline, and at 8, 6, 24, and 32 weeks
Quality of Life (QOL) (Phase 1 and 2)
Weekly patient reported quality of life measures using validated QOL questionnaires
Time frame: 9 months
| Milestone | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Started | 8 | 38 |
| Completed cycle 1 | 6 | 31 |
| Completed | 1 | 4 |
| Not completed | 7 | 34 |
Number of participants who experienced a treatment-related adverse event
| Participants | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2) | 8 | 38 |
Participants with adverse events coded using the MedDRA Dictionary (Version 20.0) to Investigations. Due to the underlying disease, not all abnormal labs are reported.
| Participants | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2) | 4 | 18 |
Number of participants with clinically significant vital sign abnormalities (Phase 1 and 2) including heart rate, respiration rate, and blood pressure
| Participants | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Number of Participants With Vital Sign Abnormalities (Phase 1 and 2) | 0 | 0 |
Number of participants with clinically significant ECG abnormalities (Phase 1 and 2)
| Participants | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2) | 0 | 0 |
| Participants | RX-3117 + Abraxane |
|---|---|
| Number of Dose-limiting Toxicities (DLTs) (Phase 1) | 0 |
Participants must have progression Free Survival (PFS) \> 4 months or objective clinical response (complete or partial response).
| Participants | RX-3117 + Abraxane Phase 2 |
|---|---|
| Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2) | 17 |
| ng*hr/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 1 | 10500 ± 6490 | 8780 ± 4460 |
| hr | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 1 | 2.3 ± 0.89 | 4.51 ± 6.18 |
| ng/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 1 | 1120 ± 516 | 947 ± 422 |
Overall Response Rate will be based on the RECIST v1.1 and is defined as the percentage of subjects meeting criteria of Complete Response (CR) or Partial Response (PR). CR or PR must be confirmed at least 4 weeks after the date of the original CR or PR.
| Participants | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Overall Response Rate [ORR] (Phase 1 and Phase 2) | 2 | 7 |
| weeks | RX-3117 + Abraxane Phase 1 |
|---|---|
| Time to Response [TTR] (Phase 1) | 23.6 (7.4 to 23.6) |
Duration of response is defined as the time from documentation of response to disease progression.
| weeks | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Duration of Response [DOR] (Phase 1 and Phase 2) | NA (19.1 to NA) | NA (16.1 to NA) |
Progression Free Survival defined as the percentage of subjects who are alive in the study and not in progression.
| weeks | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Progression-free Survival [PFS] (Phase 1) | 13.8 (7.0 to NA) | 23.3 (15.1 to 31.1) |
Time to Progression defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression.
| weeks | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Time to Progression (Phase 2) | 13.8 (7.0 to NA) | 23.4 (15.1 to 32.6) |
| ng*hr/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 15 | 1820 ± 510 | 3160 ± 1490 |
| ng*hr/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 1 | 5560 ± 2410 | 5290 ± 2120 |
| ng*hr/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 15 | 4020 ± 1710 | 3670 ± 2080 |
| hr | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 15 | 1.84 ± 0.41 | 3.75 ± 1.35 |
| hr | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 1 | 0.71 ± 0.17 | 0.62 ± 0.10 |
| hr | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 15 | 0.55 ± 0.06 | 0.69 ± 0.18 |
Results for this outcome have not been posted.
Changes in tumor burden response via tumor marker measurement
Results for this outcome have not been posted.
Weekly patient reported quality of life measures using validated QOL questionnaires
Results for this outcome have not been posted.
| ng/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15 | 528 ± 166 | 838 ± 329 |
| ng/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 1 | 4160 ± 2770 | 3940 ± 2320 |
| ng/mL | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15 | 4780 ± 2380 | 3320 ± 2330 |
Collected over Adverse event data were collected from Cycle 1 Day until Safety Follow Up (30 days after last dose). an average of 9 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RX-3117 + Abraxane Phase 1 | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| RX-3117 + Abraxane Phase 2 | 2/38 (5.3%) | 18/38 (47.4%) | 38/38 (100%) |
| Event | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/8 | 1/38 |
| AnaemiaBlood and lymphatic system disorders | 1/8 | 0/38 |
| HyperbilirubinaemiaHepatobiliary disorders | 1/8 | 0/38 |
| EmbolismVascular disorders | 1/8 | 0/38 |
| Small intestinal obstructionGastrointestinal disorders | 0/8 | 2/38 |
| Cholecystitis acuteHepatobiliary disorders | 0/8 | 2/38 |
| NeutropeniaBlood and lymphatic system disorders | 0/8 | 1/38 |
| Myocardial infarctionCardiac disorders | 0/8 | 1/38 |
| Abdominal pain upperGastrointestinal disorders | 0/8 | 1/38 |
| StomatitisGastrointestinal disorders | 0/8 | 1/38 |
| Event | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/8 | 25/38 |
| NauseaGastrointestinal disorders | 6/8 | 23/38 |
| FatigueGastrointestinal disorders | 6/8 | 23/38 |
| AlopeciaSkin and subcutaneous tissue disorders | 5/8 | 9/38 |
| Abdominal painGastrointestinal disorders | 1/8 | 20/38 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 19/38 |
| VomitingGastrointestinal disorders | 4/8 | 11/38 |
| Decreased appetiteMetabolism and nutrition disorders | 4/8 | 15/38 |
| DizzinessNervous system disorders | 2/8 | 17/38 |
| PruritusSkin and subcutaneous tissue disorders | 3/8 | 3/38 |
| Age, Continuous(years) | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 | Total |
|---|---|---|---|
| Mean | 66 ± 70.5 | 66.3 ± 66 | 66.3 ± 67 |
| Sex: Female, Male(Participants) | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 | Total |
|---|---|---|---|
| Female | 5 | 19 | 24 |
| Male | 3 | 19 | 22 |
| Ethnicity (NIH/OMB)(Participants) | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 6 |
| Not Hispanic or Latino | 7 | 32 | 39 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 4 | 4 |
| White | 8 | 34 | 42 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | RX-3117 + Abraxane Phase 1 | RX-3117 + Abraxane Phase 2 | Total |
|---|---|---|---|
| United States | 8 | 38 | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Oct 2019, 23 months.
Results were first posted in Dec 2023, 4 years 2 months after primary completion.
Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 23 months is below that.
Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Processa Pharmaceuticals